A selective, allosteric Bcr-Abl inhibitor (IC50 = 267 nM) that does not affect native c-Abl or a panel of 63 additional kinases; antiproliferative toward Bcr-Abl-transformed cells (IC50 = 138 nM), inducing apoptosis without cytotoxic consequences in nontransformed cells.